HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wingert, T. D. Articles by Hershman, J. M. Search for Related Content PubMed PubMed Citation Articles by Wingert, T. D. Articles by Hershman, J. M.

Sinemet® and thyroid function in Parkinson disease

Endocrine Research Laboratory, Veterans Administration Wadsworth Hospital Center, Department of Medicine, UCLA, Los Angeles, California.

Patients on chronic carbidopa-levodopa (Sinemet®) therapy underwent thyroid function testing that included measurement of serum thyroxine (T₄), triiodothyronine (T₃), thyrotropin (TSH), T₃uptake (T₃U), free T₄ index (FT₄I), and free T₃ index (FT₃I). The subjects were studied both in a random sampling and in a controlled manner, fasting and 2 hours after receiving the drug. All subjects were euthyroid by testing, and there was no significant difference in thyroid hormone levels of patients and controls or in fasting values and values 2 hours after the drug. However, there was a small but significant reduction in serum TSH levels after Sinemet®. Therapeutic doses of Sinemet® have no significant effect on thyroid function in euthyroid patients with Parkinson disease.